Page last updated: 2024-08-22

platinum and amrubicin

platinum has been researched along with amrubicin in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Benedetti, F; Cortinovis, D; Galetta, D; Inoue, A; Kubota, K; Makris, L; Niho, S; Nishio, M; Satouchi, M; Scagliotti, G; Valmadre, G; Yoshihara, E1
Fujisawa, M; Jimbo, N; Kimbara, S; Minami, H; Nakano, Y; Suzuki, K; Terakawa, T; Toyoda, M1
Funasaka, C; Kageyama, A; Kanemasa, Y; Omuro, Y; Shimoyama, T1

Trials

1 trial(s) available for platinum and amrubicin

ArticleYear
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 100

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Platinum; Pyrrolidines; Small Cell Lung Carcinoma; Thymine; Topotecan; Treatment Outcome; Trifluridine; Uracil

2016

Other Studies

2 other study(ies) available for platinum and amrubicin

ArticleYear
Amrubicin for Patients With Platinum-refractory Small-cell Prostate Cancer: Two Case Reports.
    Clinical genitourinary cancer, 2020, Volume: 18, Issue:3

    Topics: Aged; Anthracyclines; Antineoplastic Agents; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Platinum; Prognosis; Prostatic Neoplasms

2020
[Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:8

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome

2020